Former Galapagos CEO Paul Stoffels aims to revive cell therapy projects at new biotech Armed Cell

Paul Stoffels, who recently stepped down as chief executive of Belgian drug developer Galapagos, is turning his attention to cell‑based therapies.

After leaving Galapagos last year, Stoffels has joined a newly formed biotechnology company called Armed Cell, where he will lead efforts to restart the cell therapy programs he had initiated at Galapagos.

The move signals his continued belief in the potential of cell therapies and his intent to bring those projects back to life under the new company’s umbrella.